Heather McArthur, MD, MPH, UT Southwestern Medical Center, Dallas, TX, discusses new directions in immunotherapy for improving outcomes in triple-negative breast cancer (TNBC), including the development of better drug for patients who are high-risk and who have residual disease at the time of surgery after receiving the the Phase III KEYNOTE-522 (NCT03036488) regimen of pembrolizumab with neoadjuvant chemotherapy, as well as de-escalation of treatment for patients who are low-risk. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
